Introduction
Transient neonatal myasthenia gravis (TNMG) is a rare and usually self-limiting condition due to maternal acetylcholine receptor (AChR) antibodies in neonates born to mothers with myasthenia gravis (MG). However, a skeletal myopathy with consistent and recognizable features (termed "fetal acetylcholine receptor inactivation syndrome" or FARIS) was recently reported in some patients [1, 2] . FARIS occurs in association with clinically manifest maternal MG, or asymptomatically elevated maternal AChR antibodies directed against the fetal AChR γ subunit. Whilst in utero antibody exposure is considered the main pathogenic mechanism, the timing and intensity of maternal MG treatment plays an important role in determining fetal and postnatal outcome [1] .
The clinical spectrum of FARIS is wide, ranging from lethal arthrogryposis multiplex congenita (AMC) to mild, mainly facial myopathic manifestations persisting into adulthood [1, 3] . Whilst the symptoms of typical TNMG often respond to acetylcholine esterase inhibition or removal of causative antibodies, FARIS does not respond to the same treatments, likely reflecting antibody-mediated structural endplate alterations of antenatal onset, given that the γ-subunit is required for the assembly of pre-patterned AChR clusters and, ultimately, neuromuscular synaptogenesis [4] .
We report a child with FARIS showing dramatic symptom improvement following therapy with salbutamol (albuterol), a short-acting β2-adrenergic receptor agonist previously used effectively in specific genetic forms of congenital myasthenic syndrome (CMS).
Case Description
The proband (Patient 2.2 in [1] ) is the second child of a previously reported family affected by FARIS [1, 5] . His mother was diagnosed with MG in her first pregnancy. He had an older sibling with lethal AMC, and a younger brother with much milder symptoms, probably reflecting different treatment intensities of maternal MG over 
Conclusion
Fetal acetylcholine receptor inactivation syndrome (FARIS) [1, 2] is a recently recognized, early-onset myopathy due to maternal antibodies against the fetal AChR γ subunit which is crucial for the normal development and functioning of the embryonic neuromuscular junction (NMJ), a notion also supported by the marked abnormalities seen in patients with Escobar Allen NEUROLOGY/2015/682609 5 syndrome due to recessive mutations in the CHRNG gene [6] causing fetal AChR γ subunit disruption. Absence of myasthenic features on neurophysiological assessments [1] and lack of response to acetylcholine esterase inhibitors in the chronic stages suggested that FARIS represented an "ingrained" endplate myopathy rather than an ongoing defect of neuromuscular transmission [1] .
Salbutamol, a β2-adrenergic agonist commenced in our patient considering its proven efficacy in various neuromuscular disorders and lack of response to other treatments, resulted in dramatic and sustained improvement. Salbutamol is highly effective in genetic CMS due to mutations in several genes, most notably DOK7 and COLQ, and has been demonstrated to improve AChR cluster assembly and NMJ architecture in a mouse model of anti-MuSK MG [7] .
Taken together, our observation suggests salbutamol as an effective therapy for a potentially severe condition for which there is currently no treatment [1] . FARIS may provide a suitable model to study mechanisms of salbutamol action(s) also relevant to other neuromuscular conditions with disturbed NMJ architecture and/or function.
Level of Evidence:
This study provides Class IV evidence that salbutamol improves myasthenia-related signs in children with FARIS. This is a single observational study without controls.
